Control of bronchial asthma in Russia: results of NIKA multi-center observational study

Архипов, В. В.; Григорьева, Э. В.; Gavrishina, E.V.

doi:10.18093/0869-0189-2011-0-6-87-93

Cited by 33 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Foradil Combi ® was included into the second reference group despite the same INN for the following reasons: This medication is not a classic fixed combination and has no recommendations for use as maintenance and reliever therapy. Information about the number of patients achieving BA control was obtained from the NIKA trial [21,36]. The simulation time was 1 year and hence no discount was used.…”

Section: Methodsmentioning

confidence: 99%

“…The simulation time was 1 year and hence no discount was used. According to the selected clinical trials and the pharmacoeconomic study design, the target population was defined as adult patients over 18 with a proved diagnosis of moderate to severe BA requiring 3-4 stage GINA therapy, currently using Symbicort ® Turbuhaler ® as the sole inhaler [18,21,36].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacoeconomic analysis of continuation of use of symbicort® turbuhaler® as the sole inhaler for bronchial asthma therapy

Kulikov¹,

Makarova²

2017

Pharmacoeconom T&P

View full text Add to dashboard Cite

Control of bronchial asthma (BA) is a key principle of disease treatment. One of the factors resulting in uncontrolled BA is incorrect use of an inhalation device and, as a consequence, low adherence to therapy. According to research data, up to 94% of patients, depending on the type of delivery system, make mistakes during application, resulting in inconsistent dosage and reduced efficacy. These factors may contribute toward an increase in costs of the healthcare system and decrease in the quality of life of patients. For example, an unapproved change of the inhaler may lead to reduced BA control and, as a result, growing expenses for medical services despite lower initial costs of pharmacotherapy. Availability of a wide range of medications and devices for delivering them, as well as limited financial resources of the healthcare system inspired a pharmacoeconomic assessment of various schemes of BA therapy. According to the cost analysis results, the provided amounts of direct and indirect costs for one-year therapy with Symbicort ® Turbuhaler ® as the sole inhaler is on average 4.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Pharmacoeconomic analysis of continuation of use of symbicort® turbuhaler® as the sole inhaler for bronchial asthma therapy

Kulikov¹,

Makarova²

2017

Pharmacoeconom T&P

View full text Add to dashboard Cite

show abstract

“…В России также отсутствуют специализированные исследования эпидемиологии легкой БА. По данным многоцентрового (12 городов России, n=1000) наблюдательного исследования НИКА, среди взрослых амбулаторных пациентов с БА легкая астма наблюдалась у 17%; течение заболевания было контролируемым у 39% данных больных (при умеренной тяжести -только у 21%) [8].…”

Section: эпидемиология легкой бронхиальной астмыunclassified

Peculiarities of Mild Asthma in Russia: the Results of SYGMA2 Study

Айсанов

Рамазанович²,

Avdeev

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. Patients with mild asthma may experience severe exacerbations. This analysis was conducted to investigate regional peculiarities of mild asthma population in Russia. Materials and methods. The SYGMA2 is a double-blind multinational study involving adult patients with mild asthma (n=4176). We conducted an open-label descriptive analysis of the baseline characteristics of the Russian group (n=579) of SYGMA2 trial comparing to SYGMA2 population from other countries. The subanalysis was descriptive only, and no hypothesis were tested. Results. The Russian population of patients with mild asthma was comparable to the rest of countries in terms of demographic characteristics, smoking status and duration of asthma. The spirometric parameters in the Russian group was slightly worse than in the other population. At the study entry 48% of Russian patients had symptom control on maintenance therapy, but 52% were uncontrolled on short-acting bronchodilators. While in other countries this ratio was inverse (55/45%). More patients with mild asthma in the Russian group had at least one severe exacerbation in the previous year (30.1% vs 20.7% in other countries). Conclusion. We revealed a delayed prescription of controller therapy and overuse of short-acting bronchodilators in the Russian group of mild asthma patients, that may increase risk of asthma non-control and severe exacerbation.

show abstract

“…[Электронный ресурс] Режим доступа: https://rosmedex.ru/wp-content/ uploads/2018/02/Metodicheskie-rekomendatsii-po-raschetuzatrat-pri-provedenii-kliniko-e%60konomicheskih-issledovaniylekarstvennyih-preparatov-2017.pdf. 20 [37], около 5-10% имеют тяжелую форму (для моделирования популяции было принято равным 8%) [38,39], таким образом число пациентов с тяжелой формой атопической БА в РФ составляет около 86637. По данным «Регистра пациентов с тяжелой бронхиальной астмой на территории Российской Федерации» около 8% пациентов с БА тяжелого течения получают терапию с применением ГИБП [40,41].…”

Section: материалы и методы дизайн исследованияunclassified

Economic Aspects of Application of the Russian Biosimilar Omalizumab in Patients With Atopic Bronchial Asthma of Moderate to Severe Clinical Courses

Krysanova

Ермолаева

et al. 2021

Farm. farmakol. (Pâtigorsk)

View full text Add to dashboard Cite

A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.

show abstract

Control of bronchial asthma in Russia: results of NIKA multi-center observational study

Cited by 33 publications

References 17 publications

Pharmacoeconomic analysis of continuation of use of symbicort® turbuhaler® as the sole inhaler for bronchial asthma therapy

Pharmacoeconomic analysis of continuation of use of symbicort® turbuhaler® as the sole inhaler for bronchial asthma therapy

Peculiarities of Mild Asthma in Russia: the Results of SYGMA2 Study

Economic Aspects of Application of the Russian Biosimilar Omalizumab in Patients With Atopic Bronchial Asthma of Moderate to Severe Clinical Courses

Contact Info

Product

Resources

About